Vertex Pharmaceuticals company site
Vertex Pharmaceuticals invests in gene editing partnerships for rare diseases, largely leveraging existing delivery systems. Its scale and clinical expertise exceed Nephrogen's current stage, but it has not published kidney- or pancreas-specific AAV innovations comparable to NeFIND.
Free